Journal of Neurogastroenterology and Motility : eISSN 2093-0887 / pISSN 2093-0879

Table. 6.

Analysis of the Efficacy of Calcium Channel Blockers for Integrated Relaxation Pressure Values on High-resolution Manometry

Case Sex Age (yr) Type of achalasia IRP mmHg (before administration) Medication (dosage, mg/day) Adverse events Symptoms (after) IRP mmHg
(after administration)
Case 1 Female 40 Type II 33.4 Nifedipine (10) Nausea, vertigo No change 35.5 (failure)
Case 2 Male 39 Type I 32.1 Nifedipine (10) No change Unmeasurable
Case 3 Female 50 Type I 20.6 Nifedipine (20) No change 28.3
Case 4 Female 52 Type I 24.3 Nifedipine (10) Improved 34.7
Case 5 Female 46 Type I 34.5 Nifedipine (10) Improved 35.9
Case 6 Male 37 Type II 30.7 Nifedipine (10) Nausea, headache (Failure)
Case 7 Male 49 Type II 29.4 Nifedipine (20) Improved 28.8
Case 8 Female 46 Type II 23.2 Diltiazem (60) Improved 24.2
Case 9 Male 72 Type I 25.1 Diltiazem (90) No change 26.6

Integrated relaxation pressure (IRP) values have no significant difference on calcium channel blocker use (P = 0.063, Wilcoxon signed-rank test).

Failure: in 2 cases, due to adverse events, including nausea, vertigo, and headache, these patients could not continue the medication therapy. Unmeasurable, due to the tight lower esophageal sphincter (LES) even after the medication therapy, the catheter did not pass through the LES.

IRP, integrated relaxation pressure.

J Neurogastroenterol Motil 2022;28:562~571 https://doi.org/10.5056/jnm21254
© J Neurogastroenterol Motil